Transparency Council i.a. on drugs for leukemia and hepatocellular carcinoma

The agenda for the Transparency Council, which will meet on January 31st, is:

Preparation of positions on drug evaluation:

Venclyxto (venetoclaxum) as part of the drug program: "Treatment of patients with acute myeloid leukemia with venetoclax in combination with azacitidine (ICD-10 C92.0)",

Bavencio (avelumabum) under the drug program: "Treatment of urothelial cancer with avelumab".

Preparation of an opinion on the justification for introducing changes to the current description of the drug program: B.5 "Treatment of patients with hepatocellular carcinoma (ICD-10 c 22.0)".

Preparation of an opinion on the active substance cabozantinib used as monotherapy in the treatment of hepatocellular carcinoma (HCC) in adults after unsuccessful treatment with tyrosine kinase inhibitors or immunotherapy in combination with anti-angiogenic therapy or its intolerance, provided that clinically significant adverse effects of the previous therapy are resolved.

Preparation of an opinion on the legitimacy of introducing changes to the current description of a drug program: B.98. "Treatment of pediatric patients with chronic immune thrombocytopenia (ICD-10 D69.3)" concerning the use of the active substance romiplostim in the indication: diagnosis of persistent immune thrombocytopenia (ITP), understood as lasting longer than 6 months.

Preparation of an opinion on reimbursement of drugs containing the active substance clofarabinum in the indications: Langerhans cell histiocytosis not elsewhere classified - in the third line of treatment (ICD-10: D76.0); ACL (ICD-10: C92.0).

Source: AOTMiT